D. Serfaty - Concepedia

Author

D. Serfaty

Also Known As

D SERFATY, D Serfaty, D. SERFATY, D. Serfaty, David R Serfaty, David R. Serfaty, David Serfaty, Serfaty D., Serfaty, David

111

Publications

806

Citations

H-Index

Concepts

All Affiliations

Hôpital Saint-Louis University Hospital of Basel Azienda Ospedaliero-Universitaria di Modena Hôpital Saint-Antoine Sorbonne Université

About

D. Serfaty is an author at Hôpital Saint-Louis specializing in medicine, obstetrics, and contraceptive use.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	240
2	Public Health	3	3	81
3	Social Sciences	1	1	23
4	Endocrinology	1	1	23
5	Global Health	1	1	44

D. Serfaty

Publications

458

Citations

H-Index

Page 1

	Year	Citations
Microbiology of specimens obtained by laparoscopy from controls and from patients with pelvic inflammatory disease or infertility with tubal obstruction: Chlamydia trachomatis and Ureaplasma urealyticum J Henry‐Suchet, F Catalán, V. Loffredo, American Journal of Obstetrics and Gynecology LaparoscopyTubal ObstructionMicrobial DiseaseChlamydia TrachomatisGynecology	1980	105
Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17 -estradiol (NOMAC/E2): a double-blind, randomized study Sophie Christin‐Maître, D. Serfaty, Nathalie Chabbert‐Buffet, Human Reproduction	2011	61
European Society of Contraception Statement on Contraception in Obese Women Gabriele S. Merki‐Feld, Sven O. Skouby, D. Serfaty, The European Journal of Contraception & Reproductive Health Care Contraceptive UseContraception StatementHormonal ContraceptiveReproductive HealthGynecology	2014	44
A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene D. Serfaty, M. L. Vree The European Journal of Contraception & Reproductive Health Care	1998	33
Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism Johannes Bitzer, Jean‐Jacques Amy, Rob Beerthuizen, The European Journal of Contraception & Reproductive Health Care	2013	28
ESC expert statement on the effects on mood of the natural cycle and progestin-only contraceptives Gabriele S. Merki‐Feld, Dan Apter, G. Bártfai, The European Journal of Contraception & Reproductive Health Care Contraceptive UseHormonal ContraceptiveFertilityOral ContraceptiveReproductive Health	2017	23
How are psychotic symptoms and treatment factors affected by religion? A cross-sectional study about religious coping among ultra-Orthodox Jews D. Serfaty, Aaron D. Cherniak, Rael D. Strous Psychiatry Research PsychiatryReligion StudiesPsychotic DisorderReligiositySpirituality	2020	23
Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism Johannes Bitzer, Jean‐Jacques Amy, Rob Beerthuizen, Journal of Family Planning and Reproductive Health Care	2013	21
Reconstruction of bone defects with impacted allograft in femoral stem revision surgery Alberto Francés, Enrique Moro, Juan-Luis Cebrian, International Orthopaedics Hip ArthroplastyBone RepairSurgeryOsteoporosisImpacted Allograft	2007	19
[Premenstrual syndrome in France: epidemiology and therapeutic effectiveness of 1000 mg of micronized purified flavonoid fraction in 1473 gynecological patients]. D. Serfaty, A. C. Magneron PubMed	1997	18

Page 1